Dr. Praful M. Kelkar, MD

Dr. Kelkar practices at Minneapolis Clinic of Neurology, Ltd in Minneapolis, Minnesota.

Dr. Kelkar's NPI, 1588656417, was assigned on August 17, 2005. Dr. Kelkar holds Minnesota license 39096.

Dr. Kelkar's primary practice is Minneapolis Clinic of Neurology, Ltd, at 4225 Golden Valley Rd, Minneapolis, MN 55422 in Hennepin County. The practice phone is (763) 588-0661.

Dr. Kelkar's primary practice is Minneapolis Clinic of Neurology, Ltd in Minneapolis, Minnesota. Dr. Kelkar is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is Hennepin Healthcare. Dmand AI also links Dr. Kelkar to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kelkar practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kelkar's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kelkar is licensed in Minnesota.

CMS data shows 7,516 Medicare services from Dr. Kelkar across 13 procedure codes in 2024, for 207 Medicare patients. Medicare paid $65,274 for them.

CMS counts 207 Medicare patients who saw Dr. Kelkar in 2024. The largest group is 65 to 74, with 83 patients. 67% of them have high blood pressure, and 62% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kelkar's median patient age at 66, with 60% women.

In 2024, Dr. Kelkar wrote 1,083 Medicare Part D claims for 222 patients. 96% of them were for generic drugs. CMS names the drug for 900 of them, across 28 drugs with 11 or more claims each, at $37,080 in total drug cost. In 2023, CMS named 1,022 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Kelkar for performance year 2024, reported as part of a group. Dr. Kelkar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kelkar as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Kelkar in 2020. Dr. Kelkar's most frequent co-authors are John Brandon Davies, MD and Malik Ya Ghannam, MD.

CMS Open Payments shows 149 general payments to Dr. Kelkar from 29 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 91% of the total. Sanofi and Genzyme US Companies paid the most, $51,743.